CCORF says to keep buying Quoin Pharmaceuticals and still thinks its shares are worth $18.

QNRX · Quoin Pharmaceuticals

The AI's read

That continued view suggests the analyst still sees promise in Quoin's business. The report gives no new trial results, sales, or company forecast, so the positive signal rests on the analyst's opinion alone.